CFDE Data Portal | Search PEX19

	Label	Description
	PEX19 associations Collection (Entity type)	Associations for PEX19_associations
	PEX19 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE150244 TRIM8 knockout 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	PEX19 Gene (Entity type)	ENSG00000162735 - peroxisomal biogenesis factor 19
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE189653,GSE203344 5 V 3 FLUOXETINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 0 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS

PEX19 associations

Associations for PEX19_associations

PEX19 associations.tsv

A file from IDG as part of the Harmonizome project

GSE150244 TRIM8 knockout 3 v 0 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

A Gene Set from LINCS

PEX19

ENSG00000162735 - peroxisomal biogenesis factor 19

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE189653,GSE203344 5 V 3 FLUOXETINE MOUSE UP

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 0 v 7 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.